Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Breast Carcinoma: early-phase trial registry
5 of 11 indexed Advanced Breast Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 5 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Advanced Breast Carcinoma: 11 US clinical trials tracked, 5 recruiting.
Advanced Breast Carcinoma is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition advanced-breast-carcinoma
OPEN 5 | RECR 45% | LATE 0 | EARLY 9 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Anger (45% recruiting · 11 trials)
Advanced Breast Carcinoma lists 5 open slots (45% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Breast Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Breast Carcinoma recruits in line with its size-band peers.
5 of 11 indexed trials (45.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Breast Carcinoma research.
M.D. Anderson Cancer Center accounts for 3 of 11 trials (27.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Advanced Breast Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 11 trials that report a genuine target (sentinel values excluded). 10 of those (90.9%) plan for fewer than 100 participants.
-
Advanced Breast Carcinoma research is mostly interventional.
9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT05969860
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
M.D. Anderson Cancer Center
NCT04090567
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
NCT04704661
Living Well With Advanced Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT07227038
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
NCT05092373
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
NCT04491942
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Mayo Clinic
NCT03281902
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
NCT06630325
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03218826
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
NCT03179904
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
NCT03207529
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Breast Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Breast Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Breast Carcinoma page
11 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Advanced Breast Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Advanced Breast Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Breast Carcinoma condition card totals 11 registered trials; most-linked intervention Ceralasertib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.